The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While making revisions, conscious efforts were made to harmonize our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items [37,39,41,45,46].”
From Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“These items have been identified as important in several well-known guidelines for reporting of clinical research [4],[38]–[41].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“Most guidelines, such as the STROBE guidelines for the reporting of observational studies or the REMARK guidelines for tumour marker prognostic studies, specifically advise investigators to report both unadjusted results (i.e., from univariable analysis, yielding the association of each candidate predictor with the outcome) and adjusted results (i.e., from a multivariable analysis) [4],[38],[63].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“However, none of these guidelines are entirely appropriate for prediction model studies.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citationMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citationDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Items 601–700 of 1,003
Serum Markers for Prostate Cancer: A Rational Approach to the Literature
Steuber, T. P., O'Brien, M. F., & Lilja, H. G. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.034 · Cited by 61
Eustace, A., Irlam, J. J., Taylor, J., Denley, H., Agrawal, S. R., Choudhury, A., Ryder, W. D. J., Ord, J., Harris, A. L., Rojas, A. M., et al. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.05.017 · Cited by 57
Borley, J., Wilhelm-Benartzi, C. S., Brown, R. E., & Ghaem‐Maghami, S. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.376 · Cited by 57
Ponz‐Sarvisé, M., Nguewa, P., Pajares, M. J., Agorreta, J., Lozano, M. D., Redrado, M., Pı́o, R., Behrens, C., Wistuba, I. I., García-Franco, C. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3381 · Cited by 55
ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Manna, S., Bostner, J., Sun, Y., Miller, L. D., Alayev, A., Schwartz, N. S., Lager, E., Fornander, T., Nordenskjöld, B. A., Yu, J. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0857 · Cited by 57
Prognostic DNA Methylation Markers for Renal Cell Carcinoma: A Systematic Review
Joosten, S. C., Deckers, I. A. G., Aarts, M. J. B., Hoeben, A., van Roermund, J. G. H., Smits, K. M., Melotte, V., van Engeland, M., & Tjan‐Heijnen, V. C. G. (2017) · Epigenomics · doi:10.2217/epi-2017-0040 · Cited by 58
Veenstra, V. L., Damhofer, H., Waasdorp, C., van Rijssen, L. B., van de Vijver, M. J., Dijk, F., Wilmink, H. W., Besselink, M. G., Busch, O. R., Chang, D. K.-F., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0096-9 · Cited by 58
Zhang, J., Wang, J., Marzese, D. M., Wang, X., Yang, Z., Li, C., Zhang, H., Zhang, J., Chen, C. C., Kelly, D. F., et al. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0238-5 · Cited by 56
A 25-gene classifier predicts overall survival in resectable pancreatic cancer
Birnbaum, D. J., Finetti, P., Lopresti, A., Gilabert, M., Poizat, F., Raoul, J.-L., Delpero, J.-R., Moutardier, V., Birnbaum, D., Mamessier, E., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0936-z · Cited by 51
Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects
Popat, S., & Smith, I. E. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1090 · Cited by 56
Current Status of Molecular Biomarkers in Endometrial Cancer
Werner, H. M. J., & Salvesen, H. B. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0403-3 · Cited by 56
Al-Mufti, R., Wilbaux, M., Oza, A. M., Hénin, É., Freyer, G., Tod, M. M., Colomban, O., & You, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt382 · Cited by 56
Addison, C., Ding, K., Zhao, H., Maître, A. L., Goss, G. D., Seymour, L., Tsao, M., Shepherd, F. A., & Bradbury, P. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0805 · Cited by 56
Mallick, R., Patnaik, S. K., Wani, S. B., & Bansal, A. K. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3959-3 · Cited by 57
Saïag, P., Aegerter, P., Vitoux, D., Lebbé, C., Wolkenstein, P., Dupin, N., Descamps, V., Aractingi, S., Funck‐Brentano, E., Autier, P., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv264 · Cited by 56
Hacker, U. T., Escalona-Espinosa, L., Consalvo, N., Goede, V., Schiffmann, L. M., Scherer, S. J., Hedge, P., Cutsem, E. V., Coutelle, O., & Büning, H. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.30 · Cited by 56
Mu, S., Ai, L., Fan, F., Qin, Y., Sun, C., & Hu, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0609-9 · Cited by 56
Prediction of biochemical cure in patients with medullary thyroid cancer
Machens, A., Lorenz, K., & Dralle, H. (2020) · British journal of surgery · doi:10.1002/bjs.11444 · Cited by 56
Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer
Christgen, M., Gluz, O., Harbeck, N., Kates, R. E., Raap, M., Christgen, H., Clemens, M., Malter, W., Nuding, B., Aktas, B., et al. (2020) · Cancer · doi:10.1002/cncr.33104 · Cited by 58
Schumacher, M. C., Holländer, N., Schwarzer, G., Binder, H., & Sauerbrei, W. (2012) · Chapman & Hall/CRC eBooks · doi:10.1201/b11800-30 · Cited by 57
Self-citationMicroRNA-372 Is Associated with Poor Prognosis in Colorectal Cancer
Yamashita, S., Yamamoto, H., Mimori, K., Nishida, N., Takahashi, H., Haraguchi, N., Tanaka, F., Shibata, K., Sekimoto, M., Ishii, H., et al. (2012) · Oncology · doi:10.1159/000336809 · Cited by 55
Tissue microarrays: one size does not fit all
Eckel‐Passow, J. E., Lohse, C. M., Sheinin, Y. M., Crispen, P. L., Krco, C. J., & Kwon, E. D. (2010) · Diagnostic Pathology · doi:10.1186/1746-1596-5-48 · Cited by 55
Human epididymis protein 4 (HE4) and ovarian cancer prognosis
Trudel, D., Têtu, B., Grégoire, J., Plante, M., Renaud, M., Bachvarov, D. R., Douville, P., & Bairati, I. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.09.003 · Cited by 55
Comparative Effectiveness Research in Oncology: An Overview
Lyman, G. H., & Levine, M. N. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9792 · Cited by 55
Benard, A., Goossens-Beumer, I. J., van Hoesel, A. Q., Horati, H., de Graaf, W., Putter, H., Zeestraten, E. C. M., Liefers, G., van de Velde, C. J. �., & Kuppen, P. J. K. (2014) · Histopathology · doi:10.1111/his.12534 · Cited by 55
A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
Mihály, Z., Sztupinszki, Z. M., Surowiak, P., & Győrffy, B. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912802429265 · Cited by 55
Tomiguchi, M., Yamamoto, Y., Yamamoto‐Ibusuki, M., Goto‐Yamaguchi, L., Fujiki, Y., Fujiwara, S., Sueta, A., Hayashi, M., Takeshita, T., Inao, T., et al. (2016) · Cancer Science · doi:10.1111/cas.12897 · Cited by 55
Mu, S., Ai, L., Fan, F., Sun, C., & Hu, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-017-0498-3 · Cited by 55
Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
Wang, Y., Chen, L., Mao, Y., Li, Y.-Q., Jiang, W., Xu, S., Zhang, Y., Chen, Y., Li, X., He, Q., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000334 · Cited by 55
Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 65
Spowart, J. E., Townsend, K. N., Huwait, H., Eshragh, S., West, N. R., Ries, J., Kalloger, S. E., Anglesio, M. S., Gorski, S. M., Watson, P. H., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4090 · Cited by 55
Evidence-Based Oral and Maxillofacial Surgery
Kyzas, P. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.01.024 · Cited by 54
New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK
Hayes, D. F., Ethier, S. P., & Lippman, M. E. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9253-5 · Cited by 54
CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer
Olsen, J., Eiholm, S., Kirkeby, L. T., Espersen, M. L. M., Jess, P., Gögenür, I., Olsen, J., & Troelsen, J. T. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.11.009 · Cited by 54
Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer
Sokol, L., Koelzer, V. H., Rau, T. T., Karamitopoulou, E., Zlobec, I., & Lugli, A. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0647-1 · Cited by 54
RECQL4 helicase has oncogenic potential in sporadic breast cancers
Arora, A., Agarwal, D., Abdel‐Fatah, T. M., Lu, H., Croteau, D. L., Moseley, P. M., Aleskandarany, M. A., Green, A. R., Ball, G., Rakha, E. A., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4681 · Cited by 55
Swain, S. M., Tang, G., Brauer, H. A., Goerlitz, D. S., Lucas, P. C., Robidoux, A., Harris, B. T., Bandos, H., Ren, Y., Geyer, C. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0152 · Cited by 53
Kimbung, S., Johansson, I., Danielsson, A., Veerla, S., Brage, S. E., Stolt, M. F., Skoog, L. K., Carlsson, L. M. S., Einbeigi, Z., Lidbrink, E. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0487 · Cited by 53
Kok, M., Zwart, W. T., Holm, C., Fles, R., Hauptmann, M., Veer, L. J. V., Wessels, L. F. A., Neefjes, J., Stål, O., Linn, S. C., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0798-y · Cited by 53
Kim, H., Kim, M., Kwak, C. H., Kim, H. H., & Ku, J. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089259 · Cited by 53
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
Aleskandarany, M. A., Caracappa, D., Nolan, C. C., Macmillan, R. D., Ellis, I. O., Rakha, E. A., & Green, A. R. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3306-6 · Cited by 53
Karamitopoulou, E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00221 · Cited by 53
Hilborn, E., Gacic, J., Fornander, T., Nordenskjöld, B. A., Stål, O., & Jansson, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.464 · Cited by 53
Kim, J., Jung, H. H., Ahn, S., Bae, S., Lee, S. K., Kim, S. W., Lee, J. E., Nam, S. J., Ahn, J. S., Im, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep31804 · Cited by 54
Lundberg, A., Lindström, L. S., Harrell, J. C., Falato, C., Carlson, J. W., Wright, P. K., Foukakis, T., Perou, C. M., Czene, K., Bergh, J. C. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1535 · Cited by 53
Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis
Hu, B., Fan, H., Lv, X., Chen, S., & Shao, Z. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0562-7 · Cited by 54
RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer
Lang, J. E., Ring, A., Porras, T. B., Kaur, P., Forte, V. A., Mineyev, N. M., Tripathy, D., Press, M. F., & Campo, D. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6540-4 · Cited by 55
Machens, A., Lorenz, K., & Dralle, H. (2019) · British journal of surgery · doi:10.1002/bjs.11071 · Cited by 53
Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study
Bjarnadottir, O., Feldt, M., Inasu, M., Bendahl, P., Elebro, K., Kimbung, S., & Borgquist, S. (2020) · Scientific Reports · doi:10.1038/s41598-019-57323-9 · Cited by 52
Kim, J. C., Yu, J. H., Cho, Y. K., Jung, C. S., Ahn, S. H., Gong, G., Kim, Y. S., & Cho, D. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1868-5 · Cited by 52
Engstrøm, M. J., Opdahl, S., VATTEN, L. J., Haugen, O. A., & Bofin, A. M. (2014) · Histopathology · doi:10.1111/his.12572 · Cited by 52
Huber, F., Montani, M., Sulser, T., Jaggi, R. B., Wild, P. J., Moch, H., Gevensleben, H., Schmid, M. C., Wyder, S., & Kristiansen, G. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.588 · Cited by 52
Lipton, A., Köstler, W. J., Leitzel, K. E., Ali, S. M., Sperinde, J., Weidler, J. M., Paquet, A. C., Sherwood, T., Huang, W., Bates, M. P., et al. (2010) · Cancer · doi:10.1002/cncr.25430 · Cited by 54
A simple and reproducible breast cancer prognostic test
Marchionni, L., Afsari, B., Geman, D., & Leek, J. T. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-336 · Cited by 52
Pinder, S. E., Brown, J. P., Gillett, C., Purdie, C. A., Speirs, V., Thompson, A. M., & Shaaban, A. M. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201091 · Cited by 52
Yao, S., Barlow, W. E., Albain, K. S., Choi, J., Zhao, H., Livingston, R. B., Davis, W., Rae, J. M., Yeh, I., Hutchins, L. F., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0281 · Cited by 52
Choi, J., Barlow, W. E., Albain, K. S., Hong, C., Blanco, J. G., Livingston, R. B., Davis, W., Rae, J. M., Yeh, I., Hutchins, L. F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0685 · Cited by 52
Müller, V., Riethdorf, S., Rack, B. K., Janni, W. J., Fasching, P. A., Solomayer, E. F., Aktas, B., Kasimir‐Bauer, S., Zeitz, J., Pantel, K., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2916 · Cited by 52
Terasawa, T., Dahabreh, I. J., & Nihashi, T. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0054 · Cited by 52
Riaz, M., Sieuwerts, A. M., Look, M. P., Timmermans, M. A. M., Smid, M., Foekens, J. A., & Martens, J. W. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3317 · Cited by 50
Arora, A., Abdel-Fatah, T. M. A., Agarwal, D., Doherty, R. E., Moseley, P. M., Aleskandarany, M. A., Green, A. R., Ball, G., Alshareeda, A. T., Rakha, E. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0939 · Cited by 51
Botta, C., Martino, M. T. D., Ciliberto, D., Cucè, M., Correale, P., Rossi, M., Tagliaferri, P., & Tassone, P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.118 · Cited by 54
Fracture Risk Assessment: State of the Art, Methodologically Unsound, or Poorly Reported?
Collins, G. S., & Michaëlsson, K. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0108-1 · Cited by 51
Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer
Wood, S. L., Rogers, M., Cairns, D. A., Paul, A., Thompson, D., Vasudev, N. S., Selby, P. J., & Banks, R. E. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605720 · Cited by 51
Hemingway, H., Henriksson, M., Chen, R., Damant, J., Fitzpatrick, N. K., Abrams, K. R., Hingorani, A. D., Janzon, M., Shipley, M. J., Feder, G. S., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14090 · Cited by 51
Rothberg, B. E. G., & Rimm, D. L. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.149 · Cited by 51
Schramm, S., & Mann, G. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0901 · Cited by 51
Panis, C., Pizzatti, L., Herrera, A. C. D. S. D. A., Cecchini, R., & Abdelhay, E. S. F. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.020 · Cited by 51
Faratian, D., Sims, A. H., Mullen, P., Kay, C., Um, I., Langdon, S. P., & Harrison, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023772 · Cited by 51
Ekmekçioglu, S., Davies, M. A., Tanese, K., Roszik, J., Shin-Sim, M., Bassett, R. L., Milton, D. R., Woodman, S. E., Prieto, V. G., Gershenwald, J. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2226 · Cited by 51
Zeng, S., Zhang, Y., Ma, J., Deng, G., Qu, Y., Guo, C., Han, Y., Yin, L., Cai, C., Li, Y., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.042 · Cited by 50
Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis
Valachis, A., & Ullenhag, G. J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.015 · Cited by 51
Schürch, C. M., Forster, S., Bruehl, F. K., Yang, S. H.-Y., Felley‐Bosco, E., & Hewer, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373235 · Cited by 51
Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer
Kristiansen, G. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.168 · Cited by 51
Gallo, V., Egger, M., McCormack, V., Farmer, P. B., Ioannidis, J. P. A., Kirsch‐Volders, M., Matullo, G., Phillips, D. H., Schoket, B., Strömberg, U., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.07.010 · Cited by 55
Kuang, B.-H., Zhang, M.-Q., Xu, L.-H., Hu, L.-J., Wang, H.-B., Zhao, W.-F., Du, Y., & Zhang, X. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.439 · Cited by 50
Thagaard, J., Stovgaard, E. S., Vognsen, L. G., Hauberg, S., Dahl, A., Ebstrup, T., Doré, J., Vincentz, R. E., Jepsen, R. K., Roslind, A., et al. (2021) · Cancers · doi:10.3390/cancers13123050 · Cited by 50
Chen, Y., Chen, C., Liu, J., Chen, S.-T., Cheng, M., & Chiu, D. (2011) · Journal of neurosurgery · doi:10.3171/2011.7.jns11718 · Cited by 49
Tumour Markers and Kidney Function: A Systematic Review
Coppolino, G., Bolignano, D., Rivoli, L., Mazza, G. A., Presta, P., & Fuíano, G. (2014) · BioMed Research International · doi:10.1155/2014/647541 · Cited by 50
Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelines
Christensen, R., Bliddal, H., & Henriksen, M. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4145 · Cited by 50
van Rhijn, B. W. G., Catto, J. W. F., Goebell, P. J., Knüchel, R., Shariat, S. F., van der Poel, H. G., Sänchez‐Carbayo, M., Thalmann, G. N., Schmitz‐Dräger, B. J., & Kiemeney, L. A. L. M. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.07.002 · Cited by 50
Koelzer, V. H., Dawson, H., Andersson, E. K., Karamitopoulou, E., Masucci, G. V., Lugli, A., & Zlobec, I. (2015) · Translational research · doi:10.1016/j.trsl.2015.02.008 · Cited by 50
Multiplicities in Cancer Research: Ubiquitous and Necessary Evils
Berry, D. A. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs301 · Cited by 50
The Role of MicroRNA-200 in Progression of Human Colorectal and Breast Cancer
Bojmar, L., Karlsson, E. A., Ellegård, S., Olsson, H., Björnsson, B., Hallböök, O. J., Larsson, M., Stål, O., & Sandström, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084815 · Cited by 50
Sharma, P., Barlow, W. E., Godwin, A. K., Parkes, E. E., Knight, L. A., Walker, S. M., Kennedy, R. D., Harkin, D. P., Logan, G. E., Steele, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00693 · Cited by 49
5HTTLPR Genetic Variant and Major Depressive Disorder: A Review
Fratelli, C. F., Siqueira, J. W. S., Silva, C. M. D. S., Ferreira, E. A., & da Silva, I. C. R. (2020) · Genes · doi:10.3390/genes11111260 · Cited by 49
The CYP2C19*2 Genotype Predicts Tamoxifen Treatment Outcome in Advanced Breast Cancer Patients
van Schaik, R. H., Kok, M., Sweep, F. C. G. J., van Vliet, M., van Fessem, M., Gelder, M. E. M., Seynaeve, C., Lindemans, J. W., Wesseling, J., Veer, L. V. ‘., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.54 · Cited by 49
Chauhan, S. S., Kaur, J., Kumar, M., Matta, A., Srivastava, G., Alyass, A., Assi, J., Leong, I., MacMillan, C., Witterick, I., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.7 · Cited by 49
Woolston, C. M., Storr, S. J., Ellis, I. O., Morgan, D. A. L., & Martin, S. G. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.029 · Cited by 49
Beelen, K. J., Opdam, M., Severson, T., Koornstra, R. H. T., Vincent, A. D., Wesseling, J., Muris, J. J. F., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3598 · Cited by 48
MiRNA expression profile reveals a prognostic signature for esophageal squamous cell carcinoma
Chen, Z., Li, J., Tian, L., Zhou, C., Gao, Y., Zhou, F., Shi, S., Feng, X., Sun, N., Yao, R., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.013 · Cited by 49
Poste, G. H., Carbone, D. P., Parkinson, D. R., Verweij, J., Hewitt, S. M., & Jessup, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2206 · Cited by 49
Rutherford, T., Orr, J. W., Grendys, E. C., Edwards, R. P., Krivak, T. C., Holloway, R. W., Moore, R. G., Puls, L. E., Tillmanns, T. D., Schink, J. C., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.08.009 · Cited by 49
Loibl, S., Darb‐Esfahani, S., Huober, J., Klimowicz, A. C., Furlanetto, J., Lederer, B., Hartmann, A., Eidtmann, H., Pfitzner, B. M., Fasching, P. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0965 · Cited by 49
Chrétien, A.-S., Fauriat, C., Orlanducci, F., Rey, J., Bouvier, G., Gautherot, E., Granjeaud, S., Demerle, C., Hamel, J.-F., Cerwenka, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17747 · Cited by 49
Seo, A. N., Kang, B. W., Kwon, O. K., Park, K. B., Lee, S. S., Chung, H. Y., Yu, W., Bae, H. I., Jeon, S. W., Kang, H., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.369 · Cited by 50
Oral Microbiota—A New Frontier in the Pathogenesis and Management of Head and Neck Cancers
Metsäniitty, M., Hasnat, S., Salo, T. A., & Salem, A. (2021) · Cancers · doi:10.3390/cancers14010046 · Cited by 50
Calcified carotid artery atheroma and stroke
Mupparapu, M., & Kim, I. H. (2007) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2007.0200 · Cited by 49
The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma
Liu, A.-W., Cai, J., Zhao, X.-L., Xu, A., Fu, H.-Q., Nian, H., & Zhang, S. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.066944 · Cited by 48
Ramankulov, A., Lein, M., Johannsen, M., Schrader, M. G., Miller, K., & Jung, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00802.x · Cited by 48
Metadata
- Authors
- McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- McShane, Lisa M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-17
- Volume
- 97
- Issue
- 16
- Pages
- 1180-1184
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096910745
- Cited by
- 2,162
- References
- 46
- Citations by year
- 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
- FWCI
- 56.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Cancer Research UK
- Translational Cancer Research Network
- National Cancer Institute (MD 20892, 20892)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
- MeSH terms
- Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
